Literature DB >> 16337833

High TNF-alpha and low IL-2 producing T cells characterize active disease in Takayasu's arteritis.

Naresh Kumar Tripathy1, Prem Chand Gupta, Soniya Nityanand.   

Abstract

We have investigated intracellular production by T cells and plasma levels of TNF-alpha, IL-2 and IFN-gamma in 12 active and 10 inactive Takayasu's arteritis (TA) patients and 12 healthy controls. The active TA compared to inactive TA and controls had higher TNF-alpha (52.7 +/- 22.3% vs. 32.9 +/- 14.2% and 35.2 +/- 14.5%, respectively; P = 0. 020), lower IL-2 (19.6 +/- 13.2% vs. 36.1 +/- 10.1% and 31.2 +/- 10.3%, respectively; P = 0.010) and comparable IFN-gamma (38.6 +/- 13.9% vs. 34.2 +/- 12.4% and 34.9 +/- 11.1%, respectively; P = 0.581) producing CD3+ T cells. There was no difference in the plasma levels of the cytokines between active TA, inactive TA and controls (TNF-alpha: 79.1 +/- 94.5 vs. 72.9 +/- 120.0 and 9.5 +/- 6.7 pg/ml, P = 0.110; IL-2: 4.3 +/- 4.8 vs. 6.6 +/- 4.7 and 8.6 +/- 4.5 pg/ml, P = 0.094 and IFN-gamma: 10.1 +/- 11.3 vs. 8.8 +/- 8.7 and 8.2 +/- 6.5 pg/ml, P = 0.871, respectively). The data show an important role of these high TNF-alpha and low IL-2 producing T cells in TA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16337833     DOI: 10.1016/j.clim.2005.09.010

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  11 in total

Review 1.  Aneurysmatic disease in patients with Takayasu disease: a case review.

Authors:  S Perrotta; G Rådberg; A Perrotta; S Lentini
Journal:  Herz       Date:  2011-11-11       Impact factor: 1.443

Review 2.  Tumor necrosis factor alpha inhibitors in patients with Takayasu's arteritis refractory to standard immunosuppressive treatment: cases series and review of the literature.

Authors:  P I Novikov; I O Smitienko; S V Moiseev
Journal:  Clin Rheumatol       Date:  2013-09-01       Impact factor: 2.980

3.  Curcumin improves treatment outcome of Takayasu arteritis patients by reducing TNF-α: a randomized placebo-controlled double-blind clinical trial.

Authors:  Nan Shao; Huixin Jia; Yiwen Li; Jingying Li
Journal:  Immunol Res       Date:  2017-08       Impact factor: 2.829

4.  Relationship of HLA-B*51 and HLA-B*52 alleles and TNF-α-308A/G polymorphism with susceptibility to Takayasu arteritis: a meta-analysis.

Authors:  Si Chen; Haixia Luan; Liubing Li; Xiaoli Zeng; Tian Wang; Yongzhe Li; Hui Yuan
Journal:  Clin Rheumatol       Date:  2016-11-04       Impact factor: 2.980

Review 5.  Takayasu arteritis - epidemiology, pathogenesis, diagnosis and treatment.

Authors:  Dominika Podgorska; Rafal Podgorski; David Aebisher; Piotr Dabrowski
Journal:  J Appl Biomed       Date:  2019-01-09       Impact factor: 1.797

Review 6.  Large vessel vasculitis.

Authors:  Ashima Gulati; Arvind Bagga
Journal:  Pediatr Nephrol       Date:  2009-10-17       Impact factor: 3.714

7.  A Case Report of Takayasu's Arteritis and Ulcerative Colitis in a Pediatric Patient with Chronic Recurrent Multifocal Osteomyelitis Successfully Treated with Infliximab: Diagnostic Clues in Disease Associations and Immune Dysregulation.

Authors:  Viveka Clare De Guerra; Humaira Hashmi; Bree Kramer; Rula Balluz; Mary Beth Son; Deborah Stein; Alicia Lieberman; Mahmoud Zahra; Rabheh Abdul-Aziz
Journal:  Case Rep Rheumatol       Date:  2019-06-11

8.  Bioinformatic Analysis Identifies Three Potentially Key Differentially Expressed Genes in Peripheral Blood Mononuclear Cells of Patients with Takayasu's Arteritis.

Authors:  Renping Huang; Yang He; Bei Sun; Bing Liu
Journal:  Cell J       Date:  2017-11-04       Impact factor: 2.479

9.  Infliximab biosimilar CT-P13 therapy in patients with Takayasu arteritis with low dose of glucocorticoids: a prospective single-arm study.

Authors:  Eun Hye Park; Eun Young Lee; Yun Jong Lee; You Jung Ha; Wan-Hee Yoo; Byoong Yong Choi; Jin Chul Paeng; Hoon Young Suh; Yeong Wook Song
Journal:  Rheumatol Int       Date:  2018-09-18       Impact factor: 2.631

Review 10.  Takayasu Arteritis.

Authors:  Ricardo A G Russo; María M Katsicas
Journal:  Front Pediatr       Date:  2018-09-24       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.